CD274 and neoplasm: High concordance between PD-L1 assessments in NSCLC samples (scored by TPS measuring PD-L1 in tumor cells only) and assessments made using PD-L1 IHC 22C3 pharmDx was demonstrated using an LDT [9]; the scoring algorithm with CPS (PD-L1 in tumor cells and tumor-associated lymphocytes and macrophages) was not evaluated.